Skip to main content
Frontiers in Neurology logoLink to Frontiers in Neurology
. 2021 Mar 19;12:621936. doi: 10.3389/fneur.2021.621936

Utility of 7 Tesla Magnetic Resonance Imaging in Patients With Epilepsy: A Systematic Review and Meta-Analysis

Ji Eun Park 1,, E-Nae Cheong 2,, Da Eun Jung 3,*,, Woo Hyun Shim 1,3, Ji Sung Lee 4
PMCID: PMC8017213  PMID: 33815251

Abstract

Objective: 7 Tesla magnetic resonance imaging (MRI) enables high resolution imaging and potentially improves the detection of morphologic abnormalities in patients with epilepsy. However, its added value compared with conventional 1.5T and 3.0T MRI is unclear. We reviewed the evidence for the use of 7 Tesla MRI in patients with epilepsy and compared the detection rate of focal lesions with clinical MRI.

Methods: Clinical retrospective case studies were identified using the indexed text terms “epilepsy” AND “magnetic resonance imaging” OR “MR imaging” AND “7T” OR “7 Tesla” OR “7T” in Medline (2002-September 1, 2020) and Embase (1999-September 1, 2020). The study setting, MRI protocols, qualitative, and quantitative assessment were systematically reviewed. The detection rate of morphologic abnormalities on MRI was reported in each study in which surgery was used as the reference standard. Meta-analyses were performed using a univariate random-effects model in diagnostic performance studies with patients that underwent both 7T MRI and conventional MRI.

Results: Twenty-five articles were included (467 patients and 167 healthy controls) consisting of 10 case studies, 10 case-control studies, 4 case series, and 1 cohort study. All studies included focal epilepsy; 12 studies (12/25, 48%) specified the disease etiology and 4 studies reported focal but non-lesional (MRI-negative on 1.5/3.0T) epilepsy. 7T MRI showed superior detection and delineation of morphologic abnormalities in all studies. In nine comparative studies, 7T MRI had a superior detection rate of 65% compared with the 22% detection rate of 1.5T or 3.0T.

Significance: 7T MRI is useful for delineating morphologic abnormalities with a higher detection rate compared with conventional clinical MRI. Most studies were conducted using a case series or case study; therefore, a cohort study design with clinical outcomes is necessary.

Classification of Evidence: Class IV Criteria for Rating Diagnostic Accuracy Studies.

Keywords: epilepsy, 7 Tesla, ultra-high field, magnetic resonance imaging, systematic review

Key Points:

  • - In a systematic review, 7T MRI showed superior detection and delineation of morphologic details compared with conventional 1.5T or 3.0T MRI.

  • - 7T showed a superior detection rate of 65% compared with a 22% detection rate for 1.5T or 3.0T MRI.

  • - A cohort study in patients with epilepsy is necessary to evaluate the diagnostic performance of 7T MRI.

Introduction

Approximately 20–40% of individuals with epilepsy do not respond to anti-seizure drug therapy (1). The most effective operative management involves a focal cortical resection with excision of the epileptogenic cortex and analysis of the underlying pathologic findings (2). Chronic focal epilepsy includes mesial temporal sclerosis (MTS), focal cortical dysplasia, neoplastic lesions, cavernous hemangioma, remote cerebral infarction, and posttraumatic encephalomalacia (3). In cases of focal lesional epilepsy, resective surgery is the most effective treatment that allows patients to become seizure-free, improving their quality of life (4).

However, 20–30% of patients with focal epilepsy are “MRI-negative” on clinical MRI, meaning that they do not have an identifiable lesion on 1.5T or 3.0T MRI (5, 6). Advances in imaging techniques by 7 Tesla MRI might improve the visualization of smaller anatomical structures and allow detailed pathological findings with a high spatial resolution by reducing the voxel size related to the increased signal-to-noise (SNR) ratio (7, 8). Another important benefit is the detection of cortical gray matter lesions (8). Because a significant proportion of surgical candidates has no relevant structural MRI abnormalities on 1.5T or 3.0T MRI, the introduction of 7 Tesla MRI techniques and diagnostic tools might provide a better surgical outcomes in these patients (4, 9).

Along with the increasing recognition of 7T MRI in patients with epilepsy, several studies have reviewed the clinical value of 7T MRI (7, 10, 11). However, no studies have quantified the diagnostic value of 7T MRI in comparison with conventional 1.5T or 3.0T MRI. A unifying evidence-based systematic summary of clinical studies might reveal the clinical value of 7T MRI. We performed a systematic review and meta-analysis of published clinical reports to determine the added value of 7T compared with the diagnostic performance of 1.5T or 3T MRI and to analyze the diagnostic value of 7T MRI in patients with epilepsy.

Materials and Methods

Article Search Strategy and Study Selection

The systematic review and meta-analysis were conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis–Diagnostic Test Accuracy (PRISMA-DTA) guidelines (12). The search terms used to find studies were “epilepsy” AND “magnetic resonance imaging” OR “MR imaging” AND “7T” OR “7Tesla” OR “7T” in the MEDLINE (National Center for Biotechnology Information) and EMBASE databases. The inclusion process is shown in Figure 1. From 199 identified articles, 135 remained after the removal of duplicates. Screening of the abstracts was performed, and 68 non-epilepsy studies, 14 review articles, 9 technical notes, 3 non-MRI studies, 3 non-7T studies, and 1 case report were excluded. Only articles published in English were reviewed. Full-text reviews of the remaining 37 potentially eligible articles were performed by two experienced reviewers working in consensus (J.E.P. and W.H.S., with 11 and 26 years of experience in radiology). In this process, 6 ex-vivo studies and 6 atlas or illustration articles were excluded. Finally, 25 articles were included in the main analysis, which consisted of 10 articles reporting a diagnostic performance study.

Figure 1.

Figure 1

Flow diagram of the study selection process.

Quality Assessment

Study quality was measured using the Newcastle Ottawa scale (13) for cohorts and modifications for case-control studies and case series that converged into eight items that could be categorized into three domains: selection, confounder, and outcome for cohort studies and selection, comparability, and exposure for case-control studies and case series.

Data Extraction

All articles were reviewed by two independent board-certified radiologists and the following general data were extracted: first author, journal, year of publication, characteristics of patients with epilepsy, type of epilepsy, age, and sex at epilepsy onset. The age and sex of controls were recorded. MRI protocols and parameters were recorded as well as whether structural and functional MRI were performed. The study design was recorded as case series/case study, case control, or cohort study (14). When there were quantitative parameters, these values were extracted from the main text, tables, or figures. In studies that included healthy controls, the quantitative parameters of the healthy controls were collected separated.

Epilepsy type was followed by the International League Against Epilepsy (ILAE) classification of seizures and epilepsy (15). Epilepsy type included generalized epilepsy, focal epilepsy, combined generalized and focal epilepsy, and unknown. Then, epilepsy with structural etiology included mesial temporal lobe epilepsy (TLE) with hippocampal sclerosis, hypothalamic hamartoma, focal cortical dysplasia (FCD), polymicrogyria, and tuberous sclerosis, or acquired structural etiology including hypoxic-ischemic encephalopathy, stroke, trauma, or infection (15). Focal epilepsy included both lesional and non-lesional epilepsy, and epilepsy with clear structural etiologies were recorded as lesional.

Statistical Analysis

In 9 studies reporting a detection rate, we performed a meta-analysis to determine the epileptogenic zone when comparing 7T with 1.5T/3.T MRI. The pooled detection rate for focal lesions in patients with epilepsy was obtained by the Hartung-Knapp adjustment for random-effects models (16). Heterogeneity was evaluated using the Higgins inconsistency index (I2) test and Cochran Q test (17), and P < 0.1 in the Q test and I2 values >50% were considered to indicate significant heterogeneity (18). Publication bias was assessed by a funnel plot and Begg test, and a P < 0.1 in the Begg test indicated significant publication bias. All statistical analyses were performed using the “meta” package in R software (version 3.6.0, R Foundation for Statistical Computing, Vienna, Austria) by an expert statistician (L.J.S. with 10 years of experience).

Results

Study Characteristics and Quality Assessment

Our search process is shown in Figure 1. The basic characteristics of the 25 articles included in this study are summarized in Table 1. The studies were published in 2011 (1 article), 2013 (1 article), 2015 (1 article), 2016 (6 articles), 2017 (5 articles), 2018 (5 articles), 2019 (4 articles), and 2020 (2 articles). There were 467 patients and the mean patient number was 18.9 (standard deviation, 12.5; range, 6–66), with a mean age of 30.1 years (standard deviation, 7) with 216 men except for 2 studies with no information regarding age and sex. There were 167 healthy controls with a mean age of 32.3 years (standard deviation, 7) with 75 men and 1 study with no information regarding age and sex. Ten studies included pediatric patients.

Table 1.

Baseline characteristics of 25 studies with 7T MRI included in this analysis.

Author (year of publication) Journal Study design Assessment 7 T MRI protocols Patients with epilepsy Control
Vendor T1 T2/FLAIR T2* Others Epilepsy type Pediatric N Sex M:F Age (year) N Sex M:F Age (year)
1 Henry et al. (19) Radiology Case-control Qualitative/anithaQuantitative Magnex, Oxford, England 3D MPRAGE FSE - - TLE (HS) - 11 5:6 26 13 8:5 28
2 Pan et al. (39) Epilepsia Cohort Quantitative Varian,anitha Agilent Technologies, USA IR-GRE - - MRSI Focal - 25 7:18 33.9 - - -
3 De Ciantis et al. (26) AJNR Am. J. Neuroradiol. Case study, Add-on Qualitative Excite HDx, GE Healthcare, USA 3D FSPGR T2 FSE, FLAIR 2D GRE 3D SWAN 2D FSE-IR Polymicrogyria - 10 4:6 30.1 - - -
4 Colon et al. (20) Acta Neurol. Belg. Case study, Add-on Qualitative Achieva, Philips, Netherlands 3D T2 TSE, FLAIR GRE - FCD* - 11 7:4 37.3 - - -
5 De Ciantis et al. (27) Epilepsia Case study, Add-on Qualitative Discovery 950 MRI, GE Healthcare, USA 3D FSPGR T2 FSE, 3D FLAIR 2D GRE 3D SWAN 2D FSE-IR Focal Yes 21 12:9 24.2 - - -
6 Grouiller et al. (42) Magma Case study, Add-on Qualitative Magnetom, Siemens, Germany 3D MP2RAGE - 2D SWI EEG-fMRI Focal, lesional Yes 9 7:2 25.9 - - -
7 Kwan et al. (28) J. Neurol. Sci. Case study, Add-on Qualitative Agilent, Siemens, Germany 3D MPRAGE - SWI - TLE - 13 7:6 31.5 - - -
8 Springer et al. (21) Invest. Radiol. Case-control, Add-on Qualitative/anithaQuantitative Magnetom, Siemens, Germany MP2RAGE T2 TSE, FLAIR TSE 2D GRE DWI Focal Lesional or non-lesional - 9 Unknown Unknown 10 6:4 27.5
9 Veersema et al. (29) Epileptic Discorder. Case series Qualitative Philips, OH, USA 3D 3D 2D GRE 3D DIR FCD Yes 6 2:4 21 - - -
10 O'Hallloran et al. (43) Neuroreport Case-control Quantitative Unknown 3D MP2RAGE - - DTI Focal, non-lesional - 8 4:4 33 8 6:2 39
11 Santyr et al. (30) J. Mag. Reson. Imaging Case-control Qualitative/anithaQuantitative Agilent, Siemens, Germany 3D MPRAGE - - - TLE - 13 7:6 33.5 20 10:10 31.2
12 Stefanits et al. (31) Invest. Radiol. Case series Qualitative Magnetom, Siemens, Germany - T2 FSE - - TLE - 13 8:5 38.7 - - -
13 Veersema et al. (30) Epilepsia Open Case study, Add-on Qualitative Achieva, Philips, Netherlands 3D MPRAGE 3D T2, 3D FLAIR GRE Focal, Lesional or non-lesional - 40 Unknown 18 - - -
14 Voets et al. (32) Sci. Rep. Case-control Quantitative Siemens, Germany 3D MPRAGE - SWI MRS TLE - 12 7:5 35.2 12 3:9 29.5
15 Feldman et al. (41) Seizure Case-control Quantitative Magnetom, Siemens, Germany - T2 TSE - - Focal, Lesional, MRI-negative - 21 13: 8 33 17 11:6 33
16 Obusez et al. (22) Neuroimage Case study, Add-on Qualitative Magnetom, Siemens, Germany 3D MP2RAGE 2D TSE 3D SWI - Focal, Lesional Yes 55 36:19 31.2 - - -
17 Pittau et al. (23) J. Neuroimaging Case series Qualitative Magnetom, Siemens, Germany 3D MP2RAGE FLAIR 3D SWI DTI Focal, Lesional - 7 4:3 24.8 - - -
18 Rutland et al. (38) Seizure Case-control Quantitative Magnetom, Siemens, Germany 3D MP2RAGE T2 TSE - DTI Focal, MRI-negative - 25 9:16 31.2 25 9: 16 31.7
19 Sun et al. (24) Neuroradiology Case study, Add-on Qualitative Magnetom, Siemens, Germany 3D MPRAGE 2D T2 TSE, 3D FLAIR 3D SWI - Tuberous sclerosis Yes 10 5:5 13.2 - - -
20 Bartolini et al. (33) AJNR Am. J. Neuroradiol. Case study, Add-on Qualitative Discovery 950 MRI, GE Healthcare, USA 3D MPRAGE 2D T2 FSE, 3D FLAIR 3D SWAN, 2D GRE - FCD Yes 12 7:5 23.3 - - -
21 Feldman et al. (34) PLoS ONE Case-control, Add-on Qualitative Magnetom, Siemens, Germany 3D MPRAGE, MP2RAGE 2D T2 TSE, 3D FLAIR 2D SWI - Focal, Lesional Yes 37 20:17 36.1 21 15:6 34
22 Shah et al. (36) Hum. Brain Mapp. Case-control Quantitative Magnetom, Siemens, Germany 3D MPRAGE T2 TSE - BOLD fMRI Focal Yes 13 3:10 45.4 24 Unknown Unknown
23 Zhang et al. (25) Seizure Case study, Add-on Qualitative Unknown, Siemens, Germany 3D MPRAGE T2 FSE - - TLE Yes 39 20: 19 27.0 - - -
24 Feldman et al. (40) Epilepsia Case-control Quantitative Magnetom, Siemens, Germany 3D MPRAGE - 3D SWI Focal, MRI-negative - 34 14:20 37 17 7:10 37
25 Lampinen et al. (37) Epilepsia Case series Quantitative Achieva, Philips, Netherlands 3D TFE 3D FLAIR - DTI FCD Yes 13 8:5 32 - - -

FSPGR, fast-spoiled gradient echo; MPRAGE, magnetization prepared rapid gradient echo; MP2RAGE, variation of magnetization prepared rapid gradient echo; TLE, Temporal lobe epilepsy; FCD, Focal cortical dysplasia; yr, year; N = number.

Structural MRI included high-resolution T1, T2, and susceptibility-weighted imaging and functional MRI included diffusion tensor imaging (n = 4), functional MRI (n = 2), and MR spectroscopy (n = 2). Study design included 10 case studies, 10 case-control studies, 4 case series, and 1 cohort study.

Regarding epilepsy type, all studies included focal or combined generalized and focal epilepsy (25/25 studies). Of these, four studies included patients with focal but non-lesional epilepsy (MRI-negative) on 1.5T or 3.0T. Twelve studies (12/25, 48%) specified the etiology; of these, 6 included TLE (6/25, 24%), 4 included FCD (4/25, 16%), 1 study included polymicrogyria, and 1 study included tuberous sclerosis.

Study quality was measured with the Newcastle Ottawa scale ranging from 1 to 6 (Supplementary Data). Most studies lost points as they did not include independent validation in addition to an unclear non-response rate.

Systematic Review for Qualitative Assessment Using Structural MRI on 7T

A summary of studies according to the study endpoint, studies for meta-analysis, reliability or descriptive analyses, and potential imaging biomarkers is shown in Table 2. Qualitative assessment of morphologic characteristics on structural MRI protocols was performed for 16 studies (64%), of which a scoring system was assessed in 7 studies and the detection rate was assessed in 9 studies. In all studies with a scoring system (1925), 7T MRI scored higher than 3T MRI for lesion conspicuity of morphologic characteristics and/or reader's confidence (21). The inter-rater agreement of the diagnostic confidence scale was higher on 7T (92.3%) than on 3T (57.7%) (21).

Table 2.

Summary of 7T Epilepsy Study on 7T according to study endpoint.

No Author (year of publication) Journal Study design Assessment Qualitative/Semi-qualitative Quantitative
Study endpoint Measurement No. of readers Measurement Result Measurement Patients Healthy control
DETECTION RATE (META-ANALYSIS)
3 De Ciantis et al. (26) AJNR Am. J. Neuroradiol. Case study, Add-on Qualitative Detection 3 in consensus Count 4/6 new bilateral detection - - -
5 De Ciantis et al. (27) Epilepsia Case study, Add-on Qualitative Detection 3 in consensus Count 6/21 new detection - - -
7 Kwan et al. (28) J. Neurol. Sci. Case study, Add-on Qualitative Detection 1 Count 13/13 (7T) 10/13 (1.5 or 3.0T) - - -
9 Veersema et al. (29) Epileptic Discorder. Case series Qualitative Detection Unknown Count 4/6 (7T) 2/6 (3.0T) - - -
11 Santyr et al. (30) J. Mag. Reson. Imaging Case-control Qualitative/anithaQuantitative Detection, Morphologic abnormalities 2 4-point scale 6/9 new detection Hippocampal volumetry Per subregion Per subregion
12 Stefanits et al. (31) Invest. Radiol. Case series Qualitative Morphologic abnormalities 4 Binomial rating 8/13 detection no 3.0T - - -
13 Veersema et al. (32) Epilepsia Open Case study, Add-on Qualitative Detection 1 Count 9/40 new detection - - -
20 Bartolini et al. (33) AJNR Am. J. Neuroradiol. Case study, Add-on Qualitative Detection 2 in consensus Count 10/12 detection (7T) vs. 9/12 detection (3T) - - -
21 Feldman et al. (34) PLoS ONE Case-control, Add-on Qualitative Detection 2 in consensus Count 25/37 new detection - - -
DESCRIPTIVE OR RELIABILITY STUDY
1 Henry et al. (19) Radiology Case-control Qualitative/anithaQuantitative Hippocampal digitations 2 Likert scale 0.93 (intrarater)/0.80 (interrater) Subregional volume (ictal, CA1-3) 130 mm3 (CA1-3) 2383 (CA4- dentate) 172mm3
4 Colon et al. (20) Acta Neurol. Belg. Case study, Add-on Qualitative 7x2 morphologic features 3 Likert scale Superior 7 out of 14 items - - -
8 Springer et al. (21) Invest. Radiol. Case-control, Add-on Qualitative/anithaQuantitative Morphologic abnormalities 2 Diagnostic confidence scale (10) Interrater 92.3 % (7T)/57.7% (3T) CNR, SNR Per modality Per modality
DETECTION RATE (META-ANALYSIS)
16 Obusez et al. (22) Neuroimage Case study, Add-on Qualitative Lesion conspicuity 10 5-point scale More conspicuous on 7.0 T than 3.0T - - -
17 Pittau et al. (23) J. Neuroimaging Case series Qualitative Lesion conspicuity Unknown Descriptive More conspicuous on 7.0 T than 3.0T - - -
19 Sun et al. (24) Neuroradiology Case study, Add-on Qualitative Lesion conspicuity 3 in consensus Descriptive More conspicuous on 7.0 T than 3.0T
23 Zhang et al. (25) Seizure Case study, Add-on Qualitative Morphologic abnormalities 1 4-rating system Higher score on 7T than 3T - - -
POTENTIAL IMAGING BIOMARKERS
2 Pan et al. (39) Epilepsia Cohort Quantitative MRSI NAA/Cr > cutoff 1 Count of voxels PPV 100%, NPV 73%, Sens 82%, Spec 100% NAA/Cr 1.32 ± 0.10 1.21 ± 0.13
6 Grouiller et al. (42) Magma Case study, Add-on Qualitative Mapping of eloquent cortex Unknown Voxels Same with 1.5T or 3.0T - - -
10 O'Hallloran et al. (43) Neuroreport Case-control Quantitative - - - - U-fiber count 1,500 1,700
14 Voets et al. (35) Sci. Rep. Case-control Quantitative - - - - Hippocampal volumetry, metabolites (glutamate) Per subregion Per subregion
15 Feldman et al. (41) Seizure Case-control Quantitative - - - - Perivascular space, count 1,603 1,902
18 Rutland et al. (38) Seizure Case-control Quantitative - - - - Fiber density Per subregion Per subregion
22 Shah et al. (36) Hum. Brain Mapp. Case-control Quantitative - - - - Hippocampal volumetry, connectivity Per subregion Per subregion
24 Feldman et al. (40) Epilepsia Case-control Quantitative - - - - Vessel density (cm3) 2.1–2.4 2.7
25 Lampinen et al. (37) Epilepsia Case series Quantitative - - - - Diffusion parameter (FA, MK) Per disease Per disease

HIA, hippocampal asymmetry score; N, number; FA, fractional anisotropy; MK, mean kurtosis; CNR, contrast-to-noise ratio; SNR, signal-to-noise ratio; NAA, N-acetylacetate.

The lesion conspicuity was higher on descriptive studies of 7T using high-resolution T1-weighted imaging of magnetization-prepared rapid gradient echo (MPRAGE) and SWI. The signs of TLE include abnormal hippocampal digitations, size differences (atrophy), abnormality of shape, and increased signal (19).

The signs of FCD include increased cortical thickness, cortical thinning, abnormal sulcation, regional hypoplasia/atrophy, transmantle sign, blurring of the gray/white matter junction, T2-weighted hyperintensity, and T1-weighted hypointensity in subcortical white matter. The diagnostic confidence was superior in 7 of 14 items on 7T compared with 3T (20).

For tuberous sclerosis (24), 7T detected tuber extension beyond the margins identified on conventional 3 T MR images, which offered a better delineation of cortical abnormalities.

Meta-Analysis of the Detection Rate of 7T Compared With 3T

Nine studies assessed the detection rate of lesional epilepsy (2634), of which 9 studies (160 patients) reported a detection rate on 7T and 8 studies (152 patients) reported a detection rate on 3T (Table 2). According to the meta-analysis of 9 studies, the overall detection rate of 7T MRI was 65% (95% confidence interval [CI]: 42 %, 85%) (Figure 2A) while that of 3T MRI was 22% (95% CI: 3%, 54%) (Figure 2B). The analysis revealed heterogeneity for 7T (I2 = 85.6%) and 3T (I2 = 91.2%). A funnel plot revealed no publication bias in data of both 7T and 3T (both P > 0.01, Begg test) (Supplementary Figure).

Figure 2.

Figure 2

Forest plots show the comparison of the detection rate on 3.0T (A) and 7.0T (B) MRI. Overall detection rates of 7T and 3T MRI are 65 and 22%, respectively, showing a statistically significant difference.

The overall detection rate was 33% higher by 7T compared with 3T. There was new bilateral detection of polymicrogyria (26), as well as new detections of FCD (27, 29, 32, 33) and hippocampal abnormalities (28, 30, 31). Of note, susceptibility weighted imaging (SWI) demonstrated leptomeningeal venous abnormalities (29) or intracortical black line signs (33), which is associated with overlying focal cortical dysplasia. One study showed a histopathologic correlation between a negative finding on 7T and an epileptogenic lesion (gliosis) (27).

Systematic Review of Quantitative Assessment and Potential Imaging Biomarkers on 7T

Quantitative assessment for potential imaging biomarkers was available for 10 studies (10/25, 40%) including 4 studies with hippocampal volumetry (19, 30, 35, 36), 3 studies with diffusion tensor parameters (37) or fiber tracking (38, 43) on DTI, 2 studies with metabolites from MR spectroscopy (35, 39), 1 study with vessel density (40), 1 study with perivascular space (41), and 1 study with functional MRI (42).

Hippocampal volumetry was quantitatively measured in hippocampal subfields in all volumetric studies (19, 30, 35, 36), and identified selectively greater ipsilateral Ammon horn atrophy (19) and CA1 and CA4+dentate gyrus atrophy (30) in patients with TLE. High-angular-resolved diffusion-weighted imaging revealed lower u-fiber counts in subjects with epilepsy (43) compared with healthy controls. Hippocampal tractography demonstrated patients with left temporal seizure focus (38), exhibited increased connectivity of certain ipsilateral subfields, especially the subiculum, presubiculum, and parasubiculum, and reduced connectivity for contralateral subfields, such as CA1 and subiculum.

With improved contrast and resolution, the depiction of the perivascular space was significantly improved on 7T using axial T2-weighted TSE sequences (41). In a case control study of 21 epilepsy patients and 17 healthy controls (41), the distribution of the perivascular space was significantly more asymmetric in epilepsy patients, and the region of maximum asymmetry was within the suspected seizure onset zone in 72% of cases. Similar results were reported in a vessel density study using SWI (40) where vessel density was highly symmetric in the hippocampus in controls, whereas the mean vessel density asymmetry was greater in neocortical and MTL epilepsy patients, where the decrease in vessel density was ipsilateral to the suspected seizure onset zone.

The N-acetyl aspartate (NAA)/ Creatinine (Cr) ratio (39) and glutamate (35) on MR spectroscopic imaging (MRSI) are potential biomarkers in epilepsy. Using voxels exhibiting a decreased NAA/Cr ratio, neocortical abnormalities were detected and localized surgery was possible (35): in a study of 25 patients, the positive predictive value for the concordance of MRSI with a good outcome was 100%, the negative predictive value was 73%, with a sensitivity of 82%, and a specificity of 100%. In another study using single-voxel MR spectroscopy (35), 7 out of 8 patients had altered metabolite concentrations of glutamate, glutamine, myo-inositol, NNN, Cr, and choline, as well as markedly reduced glutamine levels of 62.5% compared with that of healthy controls.

Discussion

Our findings support the use of 7T MRI in patients with epilepsy to identify morphologic abnormalities and define subregions of anatomic structures for surgical guidance by providing a higher signal-to-noise ratio, improved image uniformity, and better spatial resolution. Structural lesions should be identified on MRI for the presurgical workup, and the epileptogenic focus should be localized for good surgical outcomes (1, 2, 4). Moreover, the potentially epileptogenic focus should be depicted to obtain target areas for subsequent electrode implantation or eliminate the need for intracranial EEG monitoring (27), thereby facilitating surgery. In patients with epilepsy, 7T MRI detected or better characterized lesions and was a more focused and less invasive approach.

Lesions of an unknown etiology are better delineated on 7T MRI. The internal structure and extent of lesions are best visible on T2- and T2*-weighted sequences in patients with FCD and hippocampal sclerosis. Particularly, the flag-like three-layer appearance with the middle hypointense line on T2-weighted images (20) in patients with FCD facilitates the visual diagnosis (20, 33). In a study involving patients with polymicrogyria, 7T MRI revealed more extensive areas and occasionally detected bilateral disease involvement (26) in patients previously assessed to have unilateral disease involvement. Moreover, high magnetic susceptibility properties improve detection of small cavernous cortical hemangioma (20) and vascular hippocampal abnormalities with the T2*-weighted sequence (40).

This meta-analysis provides quantitative summary estimates of the detection rates in clinical studies on epilepsy. Previous review articles reported that the detection of lesions in patients with epilepsy can be improved by ~23–30% (8) on 7T, but that the results were inconsistent and had not been reviewed systemically. In this meta-analysis, the pooled detection rate of 7T MRI was higher than that of 3T MRI, with overall detection rates of 65% and 22%, respectively, showing a 33% difference. Owing to a high SNR, 7T MRI offers better spatial resolution, enabling better depiction of anatomical structures. Anatomic alterations include the transmantle sign in FCD (33), irregular outer surface and irregular cortical-white matter junction in polymicrogyria (26), and disruption of the internal architecture of the hippocampus in hippocampal sclerosis (19). These findings result from a thin slice section, small voxel size, and high magnetic susceptibility of 7T MRI.

Recommended specific sequences and paradigms as potential imaging biomarkers for epilepsy on 7T MRI are the improved conventional T1/T2-weighted sequence, diffusion tensor imaging, the T2*-weighted sequence/SWI, and MR spectroscopy. Diffusion tensor-based tractography provides detailed white matter architecture and better quantification of fiber density (38, 43) and connectivity (36). T2*-weighted and SWI sequences better demonstrate cavernomas (44) and enlarged perivascular structures, indicating adjacent white matter disease (45). MR spectroscopy on 7T MRI provides high spectral resolution of molecules, thereby enabling the quantification of numerous metabolites not visible on 3.0T or 1.5T MRI (46). In addition to NAA, glutamine and glutamate (35) are metabolites that may be used to detect neurochemical abnormalities in regions exhibiting structurally normal morphology.

Our study had some limitations. First, although studies had paired data for both 3 T/1.5T and 7T MRI, comparisons of paired proportions were unavailable because articles included the detection rate but not the false-positive and false-negative, or true-negative rate in a 2 × 2 table to compare the statistical significance. Second, most of studies included a small number of patients (case study/case series) and showed heterogeneity with a low level of evidence. A prospective cohort study, with available surgical outcomes and diagnostic performance is warranted to achieve a higher level of evidence. As for the future perspective, a meta-analysis of more formalized clinical trials and larger studies would provide the clinical context and outcomes necessary for 7T MRI to become a valid clinical tool.

In conclusion, 7T MRI has value in delineating morphologic abnormalities with higher detection rate compared with clinical MRI. Most studies were conducted as case series or case studies, and a cohort study design with clinical outcomes is necessary.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author Contributions

JP and E-NC contributed to the conception of the study, analysis, and manuscript preparation. DJ revised manuscript. All authors helped to perform the analysis with constructive discussions.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Glossary

Abbreviations

MRI

magnetic resonance imaging

SNR

signal-to-noise

PRISMA-DTA

Preferred Reporting Items for Systematic Reviews and Meta-Analysis–Diagnostic Test Accuracy.

Footnotes

Funding. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (Grant Nos: NRF-2020R1A2B5B01001707 and NRF-2020R1A2C4001748) and by a grant (2020IP0097) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2021.621936/full#supplementary-material

References

  • 1.Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. (2000) 342:314–9. 10.1056/NEJM200002033420503 [DOI] [PubMed] [Google Scholar]
  • 2.Engel JJr, Wiebe S, French J, Sperling M, Williamson P, Spencer D, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Epilepsia. (2003) 44:741–51. 10.1046/j.1528-1157.2003.48202.x [DOI] [PubMed] [Google Scholar]
  • 3.Abud LG, Thivard L, Abud TG, Nakiri GS, Santos AC, Dormont D. Partial epilepsy: a pictorial review of 3 TESLA magnetic resonance imaging features. Clinics. (2015) 70:654–61. 10.6061/clinics/2015(09)10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Rao MB, Arivazhagan A, Sinha S, Bharath RD, Mahadevan A, Bhat M, et al. Surgery for drug-resistant focal epilepsy. Ann Indian Acad Neurol. (2014) 17:S124–S131. 10.4103/0972-2327.128693 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Nguyen DK, Rochette E, Leroux JM, Beaudoin G, Cossette P, Lassonde M, et al. Value of 3.0 T MR imaging in refractory partial epilepsy and negative 1.5 T MRI. Seizure. (2010) 19:475–8. 10.1016/j.seizure.2010.07.002 [DOI] [PubMed] [Google Scholar]
  • 6.Winston GP, Micallef C, Kendell BE, Bartlett PA, Williams EJ, Burdett JL, et al. The value of repeat neuroimaging for epilepsy at a tertiary referral centre: 16 years of experience. Epilepsy Res. (2013) 105:349–55. 10.1016/j.eplepsyres.2013.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Vargas MI, Martelli P, Xin L, Ipek O, Grouiller F, Pittau F, et al. Clinical neuroimaging using 7 T MRI: challenges and prospects. J Neuroimaging. (2018) 28:5–13. 10.1111/jon.12481 [DOI] [PubMed] [Google Scholar]
  • 8.Barisano G, Sepehrband F, Ma S, Jann K, Cabeen R, Wang DJ, et al. Clinical 7 T MRI: Are we there yet? A review about magnetic resonance imaging at ultra-high field. Br J Radiol. (2019) 92:20180492. 10.1259/bjr.20180492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. (2001) 345:311–8. 10.1056/NEJM200108023450501 [DOI] [PubMed] [Google Scholar]
  • 10.Balchandani P, Naidich TP. Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol. (2015) 36:1204–15. 10.3174/ajnr.A4180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rondinoni C, Magnun C, Vallota Da Silva A, Heinsen HM, Amaro EJr. Epilepsy under the scope of ultra-high field MRI. Epilepsy Behav. (2019) 2019:106366. 10.1016/j.yebeh.2019.06.010 [DOI] [PubMed] [Google Scholar]
  • 12.Mcinnes MDF Moher D Thombs BD Mcgrath TA Bossuyt PM The P-DT . Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. (2018) 319:388–96. 10.1001/jama.2017.19163 [DOI] [PubMed] [Google Scholar]
  • 13.Wells G, Shea B, O'connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale. (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis (2000). [Google Scholar]
  • 14.Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. (2003) 20:54–60. 10.1136/emj.20.1.54 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. (2017) 58:512–21. 10.1111/epi.13709 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Inthout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. (2014) 14:25. 10.1186/1471-2288-14-25 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. (2011) 343:d5928. 10.1136/bmj.d5928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Henry TR, Chupin M, Lehéricy S, Strupp JP, Sikora MA, Sha ZY, et al. Hippocampal sclerosis in temporal lobe epilepsy: findings at 7 T. Radiology. (2011) 261:199–209. 10.1148/radiol.11101651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Colon AJ, Van Osch MJ, Buijs M, Grond JV, Boon P, Van Buchem MA, et al. Detection superiority of 7 T MRI protocol in patients with epilepsy and suspected focal cortical dysplasia. Acta Neurol Belg. (2016) 116:259–69. 10.1007/s13760-016-0662-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Springer E, Dymerska B, Cardoso PL, Robinson SD, Weisstanner C, Wiest R, et al. Comparison of routine brain imaging at 3 T and 7 T. Invest Radiol. (2016) 51:469–82. 10.1097/RLI.0000000000000256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Obusez E. C., Lowe M., Oh S. H., Wang I., Jennifer B., Ruggieri P., et al. (2018). 7T MR of intracranial pathology: preliminary observations and comparisons to 3T and 1.5T. Neuroimage 168, 459–476. 10.1016/j.neuroimage.2016.11.030 [DOI] [PubMed] [Google Scholar]
  • 23.Pittau F, Baud MO, Jorge J, Xin L, Grouiller F, Iannotti GR, et al. MP2RAGE and susceptibility-weighted imaging in lesional epilepsy at 7T. J Neuroimaging. (2018) 28:365–9. 10.1111/jon.12523 [DOI] [PubMed] [Google Scholar]
  • 24.Sun K, Cui J, Wang B, Jiang T, Chen Z, Cong F, et al. Magnetic resonance imaging of tuberous sclerosis complex with or without epilepsy at 7 T. Neuroradiology. (2018) 60:785–94. 10.1007/s00234-018-2040-2 [DOI] [PubMed] [Google Scholar]
  • 25.Zhang Y, Lv Y, You H, Dou W, Hou B, Shi L, et al. Study of the hippocampal internal architecture in temporal lobe epilepsy using 7 T and 3 T MRI. Seizure. (2019) 71:116–23. 10.1016/j.seizure.2019.06.023 [DOI] [PubMed] [Google Scholar]
  • 26.De Ciantis A, Barkovich AJ, Cosottini M, Barba C, Montanaro D, Costagli M, et al. Ultra-high-field MR imaging in polymicrogyria and epilepsy. AJNR Am J Neuroradiol. (2015) 36:309–16. 10.3174/ajnr.A4116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.De Ciantis A, Barba C, Tassi L, Cosottini M, Tosetti M, Costagli M, et al. 7T MRI in focal epilepsy with unrevealing conventional field strength imaging. Epilepsia. (2016) 57:445–54. 10.1111/epi.13313 [DOI] [PubMed] [Google Scholar]
  • 28.Kwan BYM, Salehi F, Ohorodnyk P, Lee DH, Burneo JG, Mirsattari SM, et al. Usage of SWI. (susceptibility weighted imaging) acquired at 7T for qualitative evaluation of temporal lobe epilepsy patients with histopathological and clinical correlation: an initial pilot study. J Neurol Sci. (2016) 369:82–7. 10.1016/j.jns.2016.07.066 [DOI] [PubMed] [Google Scholar]
  • 29.Veersema TJ, Van Eijsden P, Gosselaar PH, Hendrikse J, Zwanenburg JJ, Spliet WG, et al. 7 tesla T2*-weighted MRI as a tool to improve detection of focal cortical dysplasia. Epileptic Disord. (2016) 18:315–23. 10.1684/epd.2016.0838 [DOI] [PubMed] [Google Scholar]
  • 30.Santyr BG, Goubran M, Lau JC, Kwan BYM, Salehi F, Lee DH, et al. Investigation of hippocampal substructures in focal temporal lobe epilepsy with and without hippocampal sclerosis at 7T. J Magn Reson Imaging. (2017) 45:1359–70. 10.1002/jmri.25447 [DOI] [PubMed] [Google Scholar]
  • 31.Stefanits H, Springer E, Pataraia E, Baumgartner C, Hainfellner JA, Prayer D, et al. Seven-tesla MRI of hippocampal sclerosis: an in vivo feasibility study with histological correlations. Invest Radiol. (2017) 52:666–71. 10.1097/RLI.0000000000000388 [DOI] [PubMed] [Google Scholar]
  • 32.Veersema TJ, Ferrier CH, Van Eijsden P, Gosselaar PH, Aronica E, Visser F, et al. Seven tesla MRI improves detection of focal cortical dysplasia in patients with refractory focal epilepsy. Epilepsia Open. (2017) 2:162–71. 10.1002/epi4.12041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Bartolini E, Cosottini M, Costagli M, Barba C, Tassi L, Spreafico R, et al. Ultra-high-field targeted imaging of focal cortical dysplasia: the intracortical black line sign in type IIb. AJNR Am J Neuroradiol. (2019) 40:2137–42. 10.3174/ajnr.A6298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Feldman RE, Delman BN, Pawha PS, Dyvorne H, Rutland JW, Yoo J, et al. 7T MRI in epilepsy patients with previously normal clinical MRI exams compared against healthy controls. PLoS ONE. (2019) 14:e0213642. 10.1371/journal.pone.0213642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Voets NL, Hodgetts CJ, Sen A, Adcock JE, Emir U. Hippocampal MRS and subfield volumetry at 7T detects dysfunction not specific to seizure focus. Sci Rep. (2017) 7:16138. 10.1038/s41598-017-16046-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Shah P, Bassett DS, Wisse LEM, Detre JA, Stein JM, Yushkevich PA, et al. Structural and functional asymmetry of medial temporal subregions in unilateral temporal lobe epilepsy: a 7T MRI study. Hum Brain Mapp. (2019) 40:2390–8. 10.1002/hbm.24530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lampinen B, Zampeli A, Björkman-Burtscher IM, Szczepankiewicz F, Källén K, Compagno Strandberg M, et al. Tensor-valued diffusion MRI differentiates cortex and white matter in malformations of cortical development associated with epilepsy. Epilepsia. (2020) 61:1701–13. 10.1111/epi.16605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Rutland JW, Feldman RE, Delman BN, Panov F, Fields MC, Marcuse LV, et al. Subfield-specific tractography of the hippocampus in epilepsy patients at 7 Tesla. Seizure. (2018) 62:3–10. 10.1016/j.seizure.2018.09.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pan JW, Duckrow RB, Gerrard J, Ong C, Hirsch LJ, Resor SRJr, et al. 7T MR spectroscopic imaging in the localization of surgical epilepsy. Epilepsia. (2013) 54:1668–78. 10.1111/epi.12322 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Feldman RE, Marcuse LV, Verma G, Brown SSG, Rus A, Rutland JW, et al. Seven-tesla susceptibility-weighted analysis of hippocampal venous structures: application to magnetic-resonance-normal focal epilepsy. Epilepsia. (2020) 61:287–96. 10.1111/epi.16433 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Feldman RE, Rutland JW, Fields MC, Marcuse LV, Pawha PS, Delman BN, et al. Quantification of perivascular spaces at 7T: A potential MRI biomarker for epilepsy. Seizure. (2018) 54:11–8. 10.1016/j.seizure.2017.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Grouiller F, Jorge J, Pittau F, Van Der Zwaag W, Iannotti GR, Michel CM, et al. Presurgical brain mapping in epilepsy using simultaneous EEG and functional MRI at ultra-high field: feasibility and first results. Magma. (2016) 29:605–16. 10.1007/s10334-016-0536-5 [DOI] [PubMed] [Google Scholar]
  • 43.O'halloran R, Feldman R, Marcuse L, Fields M, Delman B, Frangou S, et al. A method for u-fiber quantification from 7 T diffusion-weighted MRI data tested in patients with nonlesional focal epilepsy. Neuroreport. (2017) 28:457–61. 10.1097/WNR.0000000000000788 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Schlamann M, Maderwald S, Becker W, Kraff O, Theysohn JM, Mueller O, et al. Cerebral cavernous hemangiomas at 7 tesla: initial experience. Acad Radiol. (2010) 17:3–6. 10.1016/j.acra.2009.10.001 [DOI] [PubMed] [Google Scholar]
  • 45.Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. (2013) 12:822–38. 10.1016/S1474-4422(13)70124-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Godlewska BR, Clare S, Cowen PJ, Emir UE. Ultra-high-field magnetic resonance spectroscopy in psychiatry. Front. Psychiatr. (2017) 8:123. 10.3389/fpsyt.2017.00123 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.


Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA

RESOURCES